Molecular role of TGF-β, secreted from a new type of CD4+ suppressor T cell, NY4.2, in the prevention of autoimmune IDDM in NOD mice

Journal of Autoimmunity

Volumn 10, Issue 3, 1997, Pages 299-307

  Han, Hye Seung ^a   Jun, Hee Sook ^a   Utsugi, Toshihiro ^a   Yoon, Ji Won ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b Ajou University   (South Korea)

Author keywords

CD4+ suppressor T cell; IDDM; IL 2; Signal transduction; TGF

Indexed keywords

CD4 ANTIGEN; LYMPHOTOXIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNITY; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE REARRANGEMENT; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION;

EID: 0031171607     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1997.0137     Document Type: Conference Paper

References (39)

1. Bach J.F. Insulin-dependent diabetes mellitus as a β cell-targeted disease of immunoregulation. J. Autoimmun. 8:1995;439-463.
2. Rossini A.A., Greiner D.L., Friedman H.P., Mordes J.P. Immunopathogenesis of diabetes mellitus. Diabetes Rev. 1:1993;43-75.
3. Yoon, J.W. Park, Y.H. Santamaria, P. 1995, Autoimmunity of insulin-dependent diabetes, Drugs, Diet and Disease. Volume 2: Mechanistic Approaches to Diabetes, Ellis Howard of Simon and Schuster International Group, London.
4. Shizuru J.A., Taylor-Edwards C., Banks B.A., Gregory A.K., Fathman C.G. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science. 240:1988;659-662.
5. +. Science. 249:1990;1433-1436.
6. Katz J.D., Wang B., Haskins K., Benoist C., Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell. 74:1993;1089-1100.
7. Wicker L.S., Leiter E.H., Todd J.A., Renjilian R.J., Peterson E., Fischer P.A., Podolin P.L., Zijlstra M., Jaenisch R., Peterson L.B. β2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes. 43:1994;500-504.
8. ++. Diabetes. 41:1992;998-1008.
9. +. J. Immunol. 152:1994;2042-2050.
10. +. Diabetes. 45:1996;1121-1131.
11. Wong S., Wen L., Visintin I., Flavell R.A., Janeway Jr. C.A. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in the absence of CD4 T cells. J. Exp. Med. 183:1996;67-76.
12. Verdaguer J., Yoon J.W., Averil N., Utsugi T., Park B.J., Santamaria P. Acceleration of diabetes in NOD mice expressing beta cell-cytotoxic T cell-derived TcRβ transgene. J. Immunol. 157:1996;4726-4735.
13. Boitard C., Yasunami R., Dardenne M., Bach J.F. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J. Exp. Med. 169:1989;1669-1680.
14. Hutchings P.R., Cooke A. The transfer of autoimmune diabetes in NOD mice can be inhibited or accelerated by distinct cell populations present in normal splenocytes taken from young males. J. Autoimmun. 3:1990;175-185.
15. Utsugi T., Nagata M., Kawamura T., Yoon J.W. Prevention of recurrent diabetes in syngeneic islet-transplanted NOD mice by transfusion of autoreactive T lymphocytes. Transplantation. 57:1994;1799-1804.
16. Pankewycz O., Strom T.B., Rubin-Kelley V.E. Islet-infiltrating T cell clones from non-obese diabetic mice that promote or prevent accelerated onset diabetes. Eur. J. Immunol. 21:1991;873-879.
17. Reich E.P., Scaringe D., Yagi J., Sherwin R.S., Janeway Jr. C.A. Prevention of diabetes in NOD mice by injection of autoreactive T-lymphocytes. Diabetes. 38:1989;1647-1651.
18. g7+. Diabetologia. 36:1993;716-721.
19. +. J. Exp. Med. 182:1995;87-97.
20. +. J. Autoimmun. 9:1996;331-339.
21. Wahl S.M., Hunt D.A., Wong H.L., Dougherty S., McCartney-Francis N., Wahl L.M., Ellingsworth L., Schmidt J.A., Hall G., Roberts A.B., Sporn M.B. Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J. Immunol. 140:1988;3026-3032.
22. Ristow H.J. BSC-1 growth inhibitor/type beta transforming growth factor is a strong inhibitor of thymocyte proliferation. Proc. Natl. Acad. Sci. USA. 83:1986;5531-5533.
23. Ruegemer J.J., Ho S.N., Augustine J.A., Schlager J.W., Bell M.P., McKean D.J., Abraham R.T. Regulatory effects of TGF-β on IL-2- and IL-4-dependent T cell-cycle progression. J. Immunol. 144:1990;1767-1776.
24. Ranges G.E., Figaro I.S., Espevik T., Palladino M.A. Inhibition of cytotoxic T cell development by TGF-β and reversal by recombinant TNF-α J. Exp. Med. 166:1987;991-998.
25. +. J. Immunol. 151:1993;4362-4370.
26. Ihle J.N. STATs and MAPKs: obligate or opportunistic partners in signaling. BioEssays. 18:1996;95-98.
27. Winston L.A., Hunter T. Intracellular signaling: putting JAKs on the kinase MAP. Curr. Biol. 6:1996;668-671.
28. Zhang X., Blenis J., Li H., Schindler C., Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science. 267:1995;1990-1994.
29. Wen Z., Zhong Z., Darnell Jr. J.E. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 82:1995;241-250.
30. David M., Petricon III E., Benjamin C., Pine R., Weber M.J., Larner A.C. Requirements for MAP kinase (ERK2) activity in interferon α- and interferon β-stimulated gene expression through STAT proteins. Science. 269:1995;1721-1723.
31. Theze J., Alzari P.M., Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol. Today. 17:1996;481-486.
32. Miyazaki T., Kawahara A., Fujii H., Nakagawa Y., Minami Y., Liu Z., Oishi I., Silvennoinen O., Witthuhn B.A., Ihle J.N., Taniguchi T. Functional activationof Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science. 266:1994;1045-1047.
33. Ihle J.N. Cytokine receptor signalling. Nature. 377:1995;591-504.
34. Ihle J.N. STATs: signal transducers and activators of transcription. Cell. 84:1996;331-334.
35. Nielsen M., Svejgaard A., Skov S., Odum N. Interleukin-2 induces tyrosine phosphorylation and nuclear translocation of stat3 in human T lymphocytes. Eur. J. Immunol. 24:1994;3082-3086.
36. Gaffen S.L., Lai S.Y., Xu W., Groner B., Gouilleux F., Goldsmith M.A., Greene W.C. Signaling through the interleukin 2 receptor β chain activates a STAT-5-like DNA-binding activity. Proc. Natl. Acad. Sci. USA. 92:1995;7192-7196.
37. Pani G., Fischer K., Mlinaric-Rascan I., Siminovitch K.A. Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase. J. Exp. Med. 184:1996;839-852.
38. Klingmuller U., Lorenz U., Cantley L.C., Neel B.G., Lodish H.F. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of Jak2 and termination of proliferative signals. Cell. 80:1995;729-738.
39. Yi T., Mui A.L.F., Krystal G., Ihle J.N. Hematopoietic cell phosphatase associates with the interleukin-3 (IL-3) receptor β chain and down-regulates IL-3-induced tyrosine phosphorylation and mitogenesis. Mol. Cell. Biol. 13:1993;7577-7586.